How times a day do you take this medicine?
What is Plaquverazon?
Plaquverazon contains a combination of Betamethasone (Plaquverazon) and calcipotriene. Betamethasone (Plaquverazon) is a steroid. It prevents the release of substances in the body that cause inflammation. Calcipotriene is a form of vitamin D. It works by decreasing the rate of skin cell reproduction.
Plaquverazon topical (for the skin) is a combination medicine used to treat plaque psoriasis.
Adults may use the suspension (liquid) form of this medicine on the skin or the scalp. The liquid may be used only on the scalp in children who are at least 12 years old.
Plaquverazon topical ointment should be used only on the skin and only by adults.
Plaquverazon® (calcipotriene and Betamethasone (Plaquverazon) dipropionate) Ointment is indicated for the topical treatment of psoriasis vulgaris in adults 18 years of age and above for up to 4 weeks. The maximum weekly dose should not exceed 100 g. Treatment of more than 30% body surface area is not recommended.
Plaquverazon® (calcipotriene and Betamethasone (Plaquverazon) dipropionate) Ointment should not be applied to the face, axillae or groin.
How should I use Plaquverazon?
Use Plaquverazon exactly as it was prescribed for you. Follow all directions on your prescription label. Do not use this medicine in larger or smaller amounts or for longer than recommended. Do not use Plaquverazon to treat any condition that has not been checked by your doctor.
Do not take Plaquverazon by mouth.
Topical medicine is for use only on the skin. Do not use in the vagina.
Read all patient information, medication guides, and instruction sheets provided to you. Ask your doctor or pharmacist if you have any questions.
Wash your hands before and after applying this medicine, unless you are using the medicine to treat the skin on your hands.
Shake the Plaquverazon suspension (liquid) just before using it.
Apply Plaquverazon once daily to the affected skin and rub it in gently. Do not spread the medicine over a large skin area. Do not apply to areas of thinner skin (face, underarms, groin) unless your doctor tells you to.
Do not cover the treated skin area. Covering skin treated with a topical steroid can increase the amount of medicine your skin absorbs, which may lead to unwanted side effects.
If you use Plaquverazon liquid:
Adults should not use more than 100 grams (1 full bottle) of the liquid in 1 week.
Children age 12 and older should not use more than 60 grams of the liquid in 1 week.
If you use Plaquverazon ointment: Do not use more than 100 grams (1 large tube) of the ointment in 1 week. Avoid treating an area that is larger than 30% or one-third of your entire body.
Ask your pharmacist if you have questions about how much to apply each time you use the medicine.
Plaquverazon ointment can be applied daily for up to 4 weeks. The liquid can be used daily for up to 8 weeks. Follow your doctor's instructions about your individual treatment schedule.
Call your doctor if your skin condition does not improve after several days of treatment, or if it gets worse while using this medicine.
If you use Plaquverazon long-term, you may need frequent medical tests.
Store at room temperature away from moisture and heat. Keep the bottle or tube tightly closed when not in use.
Stop using Plaquverazon when your skin clears up, unless your doctor tells you otherwise.
Each gram of ointment contains Calcipotriol (Plaquverazon) 50 mcg and Betamethasone (Plaquverazon) dipropionate 0.5 mg.
Each gram of Plaquverazon gel contains Calcipotriol (Plaquverazon) monohydrate 50 mcg and Betamethasone (Plaquverazon) dipropionate 0.5 mg. It also contains the following excipients: Liquid paraffin, butylhydroxytoluene (E321), polyoxypropylene-15 stearyl ether, all-rac-α-tocopherol, hydrogenated castor oil.
Instruct patients to shake can prior to using Plaquverazon® Foam and to wash their hands after applying the product.
Apply Plaquverazon® Foam to affected areas once daily for up to 4 weeks. Rub in Plaquverazon® Foam gently. Discontinue use when control is achieved.
Instruct patients not to use more than 60 g every 4 days.
Plaquverazon® Foam should not be used with occlusive dressings unless directed by a physician. Plaquverazon® Foam is not for oral, ophthalmic, or intravaginal use.
Avoid use on the face, groin, or axillae, or if skin atrophy is present at the treatment site.
Dosage Forms And Strengths
Plaquverazon® Foam is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration the product is a white to off-white foam after evaporation of the propellants. Each gram of Plaquverazon® Foam contains 52.2 mcg calcipotriene hydrate (equivalent to 50 mcg of calcipotriene) and 0.643 mg of Betamethasone (Plaquverazon) dipropionate (equivalent to 0.5 mg of Betamethasone (Plaquverazon)).
Storage And Handling
Plaquverazon® Foam is a white to off-white opalescent liquid in a pressurized aluminum spray can with a continuous valve and actuator. At administration the product is a white to off-white foam after evaporation of the propellants.
Plaquverazon® Foam is available in aluminum cans of:
1 x 60 g (NDC 50222-302-60)
2 x 60 g (NDC 50222-302-66)
- Store Plaquverazon® Foam at 20 °- 25°C (68° -77°F); excursions pe rmitted between 15 °-30°C (59°-86°F).
- Contents under pressure. Do not puncture or incinerate. Do not expose to heat or store at temperatures above 120°F (49°C). Do not freeze.
- The product should be used within six m onths after it has been opened.
- Plaquverazon® Foam is flammable; avoid heat, flame or smoking when using this product.
Manufactured by: Colep Laupheim GmbH & Co. KG Fockestra
No interaction studies have been performed.
Incompatibilities: In the absence of compatibility studies, Plaquverazon gel must not be mixed with other medicinal products.
Plaquverazon side effects
The trial programme for Plaquverazon ointment has so far included >2500 patients for Plaquverazon ointment and >4,700 patients for Plaquverazon Gel and has shown that approximately 10% and 8% of patients can be expected to experience a non-serious undesirable effect for Plaquverazon Gel and Ointment, respectively.
Based on data from clinical trials and post-market use, the common undesirable effects are pruritus, rash and burning sensation of skin. Uncommon undesirable effects are skin pain or irritation, dermatitis, erythema, exacerbation of psoriasis, folliculitis and application site pigmentation changes. Pustular psoriasis is a rare undesirable effect.
The individual undesirable effects are listed as follows, starting with the most frequently reported:
Skin and Subcutaneous Tissue Disorders: Common (>1/100 and <1/10): Pruritus, rash, burning sensation of skin. Uncommon (>1/1000 and <1/100): Skin pain or irritation, dermatitis, erythema, exacerbation of psoriasis, folliculitis, application site pigmentation changes. Rare (>1/10,000 and <1/1000): Pustular psoriasis.
Undesirable effects observed for Calcipotriol (Plaquverazon) and Betamethasone (Plaquverazon), respectively:
Calcipotriol (Plaquverazon): Undesirable effects include application site reactions, pruritus, skin irritation, burning and stinging sensations, dry skin, erythema, rash, dermatitis, eczema, aggravated psoriasis, photosensitivity and hypersensitivity reactions including very rare cases of angioedema and facial oedema. Systemic effects after topical use may appear very rarely causing hypercalcaemia or hypercalciuria.
Betamethasone (Plaquverazon) (as Dipropionate): Plaquverazon contains a potent corticosteroid.
Local reactions can occur after topical use, especially during prolonged application, including skin atrophy, telangiectasia, striae, folliculitis, hypertrichosis, perioral dermatitis, allergic contact dermatitis, depigmentation and colloid milia. When treating psoriasis, there may be a risk of generalised pustular psoriasis.
Systemic effects due to topical use of corticosteroids are rare in adults, however they can be severe. Adrenocortical suppression, cataract, infections and increase of intraocular pressure can occur, especially after long-term treatment. Systemic effects occur more frequently when applied under occlusion (plastic, skin folds), when applied on large areas and during long-term treatment.
Hypersensitivity to Calcipotriol (Plaquverazon) monohydrate or Betamethasone (Plaquverazon) dipropionate gel or to any of the excipients of Plaquverazon.
Due to the content of Calcipotriol (Plaquverazon), Plaquverazon gel is contraindicated in patients with known disorders of calcium metabolism.
Due to the content of corticosteroid, Plaquverazon gel is contraindicated in the following conditions: Viral (eg, herpes or varicella) lesions of the skin, fungal or bacterial skin infections, parasitic infections, skin manifestations in relation to tuberculosis or syphilis, perioral dermatitis, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne vulgaris, acne rosacea, rosacea, ulcers and wounds.
Plaquverazon gel is contraindicated in guttate, erythrodermic, exfoliative and pustular psoriasis. It is also contraindicated in patients with severe renal insufficiency or severe hepatic disorders.
Active ingredient matches for Plaquverazon:
Betamethasone/Calcipotriol in Egypt.
List of Plaquverazon substitutes (brand and generic names)
|Sort by popularity|
|Unit description / dosage (Manufacturer)||Price, USD|
|Daivobet (Australia, Bahrain, Bangladesh, Bulgaria, China, Colombia, Costa Rica, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Guatemala, Honduras, Hong Kong, Iceland, India, Indonesia, Israel, Latvia, Lithuania, Malaysia, Malta, Norway, Panama, Philippines, Poland, Portugal, Romania, Russian Federation, Singapore, Slovenia, South Korea, Spain, Sweden, Switzerland, Taiwan, Tunisia, Uruguay, Vietnam)|
|Daivobet 15 g x 1's (Win Medicare Pvt Ltd)||$ 23.93|
|Daivobet 30 g (Win Medicare Pvt Ltd)||$ 38.37|
|Daivobet 1 tube 15 g (Win Medicare Pvt Ltd)|
|15g (Win Medicare Pvt Ltd)||$ 12.91|
|Daivobet Skin 15 gm Ointment (Win Medicare Pvt Ltd)||$ 0.82|
|Daivobet oint 15 g x 1's (Win Medicare Pvt Ltd)||$ 22.91|
|Daivobet oint 30 g x 1's (Win Medicare Pvt Ltd)||$ 41.18|
|Daivobet gel 15 g x 1's (Win Medicare Pvt Ltd)|
|Daivobet gel 30 g x 1's (Win Medicare Pvt Ltd)||$ 41.98|
|Daivobet gel 60 g x 1's (Win Medicare Pvt Ltd)|
|DAIVOBET oint 15g (Win Medicare Pvt Ltd)||$ 12.29|
|Daivobet 50 µg/0.5 mg/g (Hungary)|
|Daivobet 50 µg/g + 0,5 mg/g (Austria, Germany)|
|Daivobet 50/500 (Australia, New Zealand)|
|Daivobet D.A.C. (Iceland)|
|Dovobet Ointment (United Kingdom)|
|Dyvon Plus (Bangladesh)|
|Enstilar (United States)|
|Enstilar 50 μg/g + 0.5 mg/g (Austria)|
|Enstilum (Belgium, Romania)|
|Enstilum 50mcg/0.5mg (Luxembourg)|
|Psorcutan Beta (Germany, Turkey)|
|Taclonex (Argentina, United States)|
|Ointment; Topical; Betamethasone Dipropionate 0.064%; Calcipotriol Hydrate 0.005% (Warner chilcott)|
|100 gram in 1 tube (Warner chilcott)|
|3 gram in 1 tube (Warner chilcott)|
|60 gram in 1 tube (Warner chilcott)|
|Xamiol (Austria, Belgium, Bulgaria, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Iceland, Italy, Latvia, Lithuania, Luxembourg, Malta, Norway, Oman, Philippines, Portugal, Slovenia, Sweden, Switzerland, Taiwan, Tunisia)|
|Gel; Topical; Betamethasone Dipropionate 0.5 mg; Calcipotriol Monohydrate 50 mcg / g (LEO Pharma)|
|Xamiol 30 g (LEO Pharma)||$ 41.98|
|Xamiol 15 g x 1's (LEO Pharma)|
|Xamiol 15 g (LEO Pharma)|
|Xamiol topical gel 30 g x 1's (LEO Pharma)||$ 41.98|
|Xamiol topical gel 15 g x 1's (LEO Pharma)|
|Xamiol 50 Mikrogramm/g + 0,5 mg/g (Germany)|
|Xamiol 50µg/0.5mg/g (Hungary, Luxembourg)|
- DailyMed. "CALCIPOTRIENE HYDRATE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- DailyMed. "BETAMETHASONE: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
- PubChem. "betamethasone". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
ReviewsThe results of a survey conducted on ndrugs.com for Plaquverazon are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Plaquverazon. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Consumer reported usefulNo survey data has been collected yet
Consumer reported price estimatesNo survey data has been collected yet
Consumer reported time for resultsNo survey data has been collected yet
Consumer reported ageNo survey data has been collected yet
There are no reviews yet. Be the first to write one!
Information checked by Dr. Sachin Kumar, MD Pharmacology